saroglitazar (lipaglyn)
DESCRIPTION
Saroglitazar, LipaglynTRANSCRIPT
![Page 1: SAROGLITAZAR (LIPAGLYN)](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b1960b4c9055d098b4ed4/html5/thumbnails/1.jpg)
LIPAGLYN(Saroglitazar)
for DIABETIC DYSLIPIDEMIA
Dr. T. Vijay bhushanam M.B.B.S, M.D
![Page 2: SAROGLITAZAR (LIPAGLYN)](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b1960b4c9055d098b4ed4/html5/thumbnails/2.jpg)
Objectives
• Diabetic dyslipidemia– Components– Complications– Treatment– Need for novel treatment
• LIPAGLYN (Saroglitazar)– Mechanism of action– Clinical trials.
• Summary
![Page 3: SAROGLITAZAR (LIPAGLYN)](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b1960b4c9055d098b4ed4/html5/thumbnails/3.jpg)
Diabetic dyslipidemiaComponents
1. High Tryglycerides
2. Low HDL-c
3. Postprandial lipemia
![Page 4: SAROGLITAZAR (LIPAGLYN)](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b1960b4c9055d098b4ed4/html5/thumbnails/4.jpg)
Diabetic dyslipidemiaComplications
Hyperglycemia: – Macrovascular complications:
• CVD
– Microvascular complications: • Retinopathy, Nephropathy, Neuropathy
Dyslipidemia: – Macrovascular complications
• Hypertriglyceridemia in T2DM patients increases the CV risk by 3 times.
– Microvascular complications• Hypertriglyceridemia in T2DM patients increases the risk of diabetic
kidney disease by 2-folds.*
* Sacks FM, Hermans MP, Fioretto P et al. Association between plasma triglycerides and HDL-cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes: A global case-control study in 13 countries. Circulation 2013 Dec 18.
![Page 5: SAROGLITAZAR (LIPAGLYN)](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b1960b4c9055d098b4ed4/html5/thumbnails/5.jpg)
Diabetic dyslipidemiaTreatment and Benefits
• Glycemic control– Microvascular benefits: Well proven– Macrovascular benefits : Proven
• PPAR-γ agonists: – Microvascular benefits : Well proven– Macrovascular benefits : Reduce CV end points (Death, MI, stroke)
significantly (by 16-18%) in DM patients *
• PPAR-α agonists: – Microvascular benefits : Prevent progression of early-stage diabetic
retinopathy**– Macrovascular benefits : Proven **
* PROactive study. JA Dormandy et al, Lancet 2005; 366: 1279–89. Lincoff et al. JAMA 2007;298:1180-1188** FIELD study. Lancet 2007;370:1687-97. ACCORD Eye Study Group. New Engl J Med 2010;363:233-44. Fenofibrate: a new treatment for diabetic retinopathy. Molecular mechanisms and future perspectives. Curr Med Chem 2013; 20:3258-66.
![Page 6: SAROGLITAZAR (LIPAGLYN)](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b1960b4c9055d098b4ed4/html5/thumbnails/6.jpg)
Diabetic dyslipidemia What is needed in the management
• Treating both Hyperglycemia and dyslipidemia is the comprehensive management of Diabetic dyslipidemia
• Statins are the first line drugs for diabetic dyslipidemia, but still a significant proportion of residual risk (≈75%) remains, requiring add on therapies
• PPAR agonists (α and γ) have hypolipidemic and antihyperglycemic effects with proven macro- and micro-vascular benefits, but there are concerns for safety
![Page 7: SAROGLITAZAR (LIPAGLYN)](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b1960b4c9055d098b4ed4/html5/thumbnails/7.jpg)
Diabetes. 2005 Aug;54(8):2460-70
Diabetic dyslipidemia What is needed in the management
Dual PPAR-α/γ agonists
![Page 8: SAROGLITAZAR (LIPAGLYN)](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b1960b4c9055d098b4ed4/html5/thumbnails/8.jpg)
LIPAGLYN – Saroglitazar World’s first approved dual PPAR-α/γ agonist
![Page 9: SAROGLITAZAR (LIPAGLYN)](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b1960b4c9055d098b4ed4/html5/thumbnails/9.jpg)
Spectrum of PPAR activity of various agents : Each PPAR agonist is unique
Adapted from - http://www.theheart.org/documents/sitestructure/en/content/programs/1228135/1228135.html
*Illustrative chart
![Page 10: SAROGLITAZAR (LIPAGLYN)](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b1960b4c9055d098b4ed4/html5/thumbnails/10.jpg)
Published Sept 2013 Clinical Drug Investigation
![Page 11: SAROGLITAZAR (LIPAGLYN)](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b1960b4c9055d098b4ed4/html5/thumbnails/11.jpg)
Phase 3: PRESS V Lipaglyn vs Pioglitazone in Diabetic
dyslipidemia
11
![Page 12: SAROGLITAZAR (LIPAGLYN)](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b1960b4c9055d098b4ed4/html5/thumbnails/12.jpg)
![Page 13: SAROGLITAZAR (LIPAGLYN)](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b1960b4c9055d098b4ed4/html5/thumbnails/13.jpg)
Phase 3: PRESS V Lipaglyn Vs Pioglitazone: Safety assessment
13Pai V et al. J Diabetes Sci Technol 16 Jan 2014
![Page 14: SAROGLITAZAR (LIPAGLYN)](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b1960b4c9055d098b4ed4/html5/thumbnails/14.jpg)
Critical Parameters Benefits
Weight Gain • There was no increase in the weight in Lipaglyn group,
• However Pioglitazone has shown an average increase of 1.6 kg
Cardiovascular safety 2D Echo and ECG Examinations No change in cardiac function
No edema observed
Safety and Tolerance Lipaglyn demonstrated no significant change in :
• LFT : (No DILI)• RFT: (Creatinine / eGFR)• CPK • Hemoglobin
Phase 3: PRESS V Lipaglyn Vs Pioglitazone: Advantages
![Page 15: SAROGLITAZAR (LIPAGLYN)](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b1960b4c9055d098b4ed4/html5/thumbnails/15.jpg)
Phase 3: PRESS VI Lipaglyn Vs Placebo in
Diabetic dyslipidemia on Atorvastatin
15
![Page 16: SAROGLITAZAR (LIPAGLYN)](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b1960b4c9055d098b4ed4/html5/thumbnails/16.jpg)
Phase 3: PRESS VILipaglyn Vs Placebo: Results
Primary Efficacy end point: TG reduction
Effect on other lab parameters
![Page 17: SAROGLITAZAR (LIPAGLYN)](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b1960b4c9055d098b4ed4/html5/thumbnails/17.jpg)
Phase 3: PRESS VI Lipaglyn Vs Placebo: Safety assessment
![Page 18: SAROGLITAZAR (LIPAGLYN)](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b1960b4c9055d098b4ed4/html5/thumbnails/18.jpg)
Phase 3: PRESS VILipaglyn Vs Placebo: Adverse events
![Page 19: SAROGLITAZAR (LIPAGLYN)](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b1960b4c9055d098b4ed4/html5/thumbnails/19.jpg)
Summary
• Current standards of care for blood glucose, blood pressure and LDL-C leaves behind a high level of residual vascular risk, including microvascular and macrovascular complications.
• Statin therapy alone is not sufficient for all-at risk patients (AACE response to AHA/ACC 2013 cholesterol guidelines)
• Targeting Diabetic dyslipidaemia (High TG, High Non-HDL, Low HDL) with non statin therapies is required along with statins.
• LIPAGLYN is the best available option with Hypolipidemic and Antihyperglycemic effects (↓TG, ↓Non-HDL, ↓HbA1C) and insulin sensitizing actions.
![Page 20: SAROGLITAZAR (LIPAGLYN)](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b1960b4c9055d098b4ed4/html5/thumbnails/20.jpg)
*The above values are as per International Standards Regular monitoring of blood sugars at home with the help of a glucometer is recommended and also maintenance of a SMBG (Self Monitoring of Blood Glucose) chart, which should be showed to your Diabetologist during every visit.
![Page 21: SAROGLITAZAR (LIPAGLYN)](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b1960b4c9055d098b4ed4/html5/thumbnails/21.jpg)
THANK YOU